Related Experiment Video
Updated: May 27, 2026
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Prognostic value of platelet count in diffuse large B-cell lymphoma
Ling-Ping Chen1, Shyh-Jer Lin, Ming-Sun Yu
1Division of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung, Taiwan, R.O.C. xguaalu@yahoo.com.tw
Clinical Lymphoma, Myeloma & Leukemia
|December 6, 2011
Summary
Low platelet count at diagnosis is a significant predictor of poor survival in diffuse large B-cell lymphoma (DLBCL). This finding offers a simple yet valuable tool for risk stratification in aggressive lymphoma patients.
Area of Science:
- Hematology
- Oncology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with established prognostic factors.
- The International Prognostic Index (IPI) is widely used, but optimal risk stratification remains an area of research.
- The prognostic significance of various parameters beyond IPI in DLBCL requires further clarification.
Purpose of the Study:
- To investigate the prognostic value of platelet count at the time of DLBCL diagnosis.
- To determine if thrombocytopenia is an independent predictor of survival outcomes in DLBCL patients.
- To assess the utility of platelet count as a simple risk stratification tool.
Main Methods:
- Retrospective analysis of 100 DLBCL patients treated with R-CEOP chemotherapy between 2000 and 2009.
- Evaluation of patient characteristics, including platelet count, B symptoms, bone marrow involvement, and stage.
- Multivariate analysis to assess the independent prognostic impact of thrombocytopenia on overall survival (OS) and progression-free survival (PFS).
Main Results:
- 17 patients (17%) presented with thrombocytopenia (< 150 × 10(9)/L) at diagnosis.
- Thrombocytopenic patients showed significantly more B symptoms, bone marrow involvement, advanced stage, and higher IPI scores.
- Thrombocytopenia was an independent poor prognostic factor for both OS (HR 3.405, P = .006) and PFS (HR 4.299, P = .001).
Conclusions:
- Platelet count at diagnosis serves as a simple and valuable indicator for predicting survival in DLBCL.
- Thrombocytopenia is associated with poorer outcomes in DLBCL patients treated with R-CEOP.
- Further research is needed to elucidate the mechanisms underlying the predictive value of thrombocytopenia in lymphoma.